Barclays PLC Has $1.22 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Barclays PLC boosted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 141.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 116,024 shares of the biotechnology company's stock after purchasing an additional 67,948 shares during the period. Barclays PLC owned about 0.23% of REGENXBIO worth $1,217,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Integral Health Asset Management LLC boosted its stake in shares of REGENXBIO by 25.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Quest Partners LLC boosted its position in REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company's stock valued at $491,000 after buying an additional 41,645 shares in the last quarter. BNP Paribas Financial Markets boosted its position in REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock valued at $214,000 after buying an additional 17,533 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of REGENXBIO by 630.9% during the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company's stock worth $1,711,000 after buying an additional 126,249 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of REGENXBIO during the second quarter worth $494,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright cut their price target on REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, November 21st. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, September 20th. Raymond James reiterated an "outperform" rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $35.00 price target on shares of REGENXBIO in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $35.27.

REGENXBIO Stock Down 2.4 %

REGENXBIO stock traded down $0.18 during trading hours on Monday, reaching $7.23. 1,757,332 shares of the company's stock were exchanged, compared to its average volume of 721,488. The firm has a market capitalization of $358.21 million, a PE ratio of -1.44 and a beta of 1.24. The firm's 50 day simple moving average is $9.27 and its 200 day simple moving average is $10.93. REGENXBIO Inc. has a twelve month low of $7.15 and a twelve month high of $28.80.

Insider Activity at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now directly owns 11,286 shares of the company's stock, valued at $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.13% of the stock is owned by corporate insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.